Structure via PubChem · Public domain (PubChem)
perampanel
Sign in to saveAlso known as E2007, ER-155055-90, Fycompa®, E 2007, 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, pérampanel, Perampanelum
Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai that is used in addition to other medications to treat partial seizures and generalized tonic–clonic seizures. Perampanel is a non-competitive AMPA glutamate receptor antagonist. It is taken by mouth.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 408536313
- Drug.image
- Perampanel skeletal formula from xtal 2023.svg
- Drug.image_class
- skin-invert-image
- Drug.alt
- Skeletal formula of perampanel
- Drug.width
- 200
- Drug.image2
- Perampanel ball-and-stick model from xtal 2023.png
- Drug.image_class2
- bg-transparent
- Drug.alt2
- Ball-and-stick model of the perampanel molecule
- Drug.tradename
- Fycompa
- Drug.MedlinePlus
- a614006
- Drug.DailyMedID
- Perampanel
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.class
- Anticonvulsant
- Drug.ATC_prefix
- N03
- Drug.ATC_suffix
- AX22
via Wikipedia infobox
Chemical data
- Formula
- C23H15N3O
- Molecular weight
- 349.4 g/mol
- IUPAC name
- 2-(2-oxo-1-phenyl-5-pyridin-2-yl-3-pyridinyl)benzonitrile
- SMILES
- C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4
- InChIKey
- PRMWGUBFXWROHD-UHFFFAOYSA-N
- XLogP
- 3.4
- Polar surface area
- 57 Ų
- H-bond donors
- 0
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2012
- Admin. routes
- oral
- Indications
- epilepsy, Seizure, essential tremor, diabetic neuropathy
via ChEMBL · EBI
Research
1,213 papers- Perampanel: Does it have broad-spectrum potential?Epilepsia · 2019
- Perampanel add-on for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2023
- ALSUntangled 48: Perampanel (Fycompa).Amyotrophic lateral sclerosis & frontotemporal degeneration · 2019
- Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence.Epilepsy & behavior : E&B · 2022
- Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 349.121512
- Has use
- medication
Show 8 more facts
- chemical formula
- C₂₃H₁₅N₃O
- legal status (medicine)
- boxed warning
- canonical SMILES
- C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4
- World Health Organisation international non-proprietary name
- perampanel
- defined daily dose
- 8
- medical condition treated
- tonic–clonic seizure
- significant drug interaction
- sodium oxybate
- Commons category
- Perampanel
Sources (8)
via Wikidata · CC0
~8 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Chemistry
- History
- Research
- References
Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai that is used in addition to other medications to treat partial seizures and generalized tonic–clonic seizures. Perampanel is a non-competitive AMPA glutamate receptor antagonist. It is taken by mouth.
Perampanel was approved in 2012, and , its optimal role in the treatment of epilepsy relative to other drugs is not clear. It is the first anti-epileptic drug in the class of selective non-competitive antagonist of AMPA receptors.
Excerpted from Wikipedia’s “perampanel” article, available under the CC BY-SA 4.0 licence.